An open label study for Collection of Human Blood Sample for Development of Anti-Vi IgG testing standard, in process of developing a new Conjugate Vaccine for Typhoid Enteric fever caused by Salmonella Typhi - None

Biological ELimited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1. Provide voluntary written and signed informed consent from volunteer.
•2. Healthy subjects aged 18 to 30 years of both gender.
•3. Are not participating in or plan to participate in another research during the next three months & be available throughout study period.
•4. Family does not plan to move during the study period, and housed not further that 50 KM away from the study site.

•1. Fever of any origin or infections more than 3 days within one month prior
•to screening or on the day of screening
•2. Any confirmed or suspected immunosuppressive condition.
•3. Use of any marketed or investigational or herbal medicine or non-registered drug or vaccine for typhoid.
•4. In receipt of systemic immunosuppressant or systemic corticosteroids.
•5. Prior or anticipated receipt of immune globulin or other blood products, or other immune modulator therapy.
•6. Life threatening or serious cardiac, respiratory, gastrointestinal, hepatic, renal, endocrine and systemic disorders.
•7. Have been vaccinated against typhoid fever or had exposure to typhoid fever within the last three years.
•8. Suspected or known hypersensitivity to any of the investigational or marketed vaccine components.
•9. Any condition that, in the opinion of the investigator, would pose a health risk to the participant, or interfere with the evaluation of the study objectives.

发起方

Biological ELimited